Friday, 18 Jan 2019

You are here

Comorbidities Undermine Clinical Outcomes in Psoriatic Arthritis

Analysis of data from the DANBIO registry of psoriatic arthritis (PsA) patients treated with tumor necrosis factor inhibitor (TNFi) therapy shows that comorbidities were associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates to TNFi.

Investigators studied 1,750 PsA patients and assessed comorbidities using the Charlson Comorbidity Index (CCI). Patients with higher CCI scores were generally older and female, had a longer PsA disease duration, and had a higher BMI compared with patients without comorbidities. Those with higher CCI scores were more likely to have PsA‐related diseases (psoriasis, inflammatory bowel disease, uveitis, and urethritis). A CCI of 2 or higher was seen in 191 patients (9.6%).

Higher levels of comorbidity (higher CCI scores) were associated with: 

  • higher disease activity measures at baseline
  • increased occurrence of depression and/or anxiety
  • shorter TNFi persistence with CCI score ≥2 

These findings are novel and support the importance of monitoring and treating comorbidities in patients with PsA.

Comorbidities are common, but are not commonly dealt with in rheumatology daily practice. The impact of comorbidity has been seen in other recent studies.

Strober and colleagues have also recently reported that PsA patients with metabolic syndrome-related co-morbidities have lower TNFi persistence. (Citation source: http://bit.ly/2Fz9zi7). Switching to a second TNFi was effective in some, but these too had lower TNFi persistence, suggesting the validity of switching to a second TNFi.

Lastly, it is well known that obesity and decreased therapeutic responses are linked. Holgard et al studied 2 different registries and demonstrated that TNFI adherence was shorter in obese patients, especially among men who were obese (P < 0.01 vs non-obese). In multivariable analyses, obesity increased the risk of TNFI withdrawal [hazard ratio 1.6 (95% CI 1.3, 2.0)] and reduced odds for EULAR good or moderate responses [odds ratio 0.47 (95% CI 0.29, 0.72)]. Obesity was associated with higher disease activity and seemed to diminish response and adherence to TNFIs in PsA.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.

Psoriatic Arthritis Does Not Add to Pregnancy Problems

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

This study is relevant as the average onset age of PsA ranges between the 4th-6th decades of life and therefore includes a period of child-bearing potential.

IL-23 Outduels IL-17 Inhibition in Psoriasis

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.